Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.
- Submitting institution
-
University College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 12257
- Type
- D - Journal article
- DOI
-
10.1016/j.ymthe.2017.03.002
- Title of journal
- Molecular therapy : the journal of the American Society of Gene Therapy
- Article number
- -
- First page
- 1234
- Volume
- 25
- Issue
- 5
- ISSN
- 1525-0016
- Open access status
- Compliant
- Month of publication
- March
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
7
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- This report demonstrates an important advancement in the specificity of a promising immunotherapy modality by avoiding harmful off-tumour killing. We showed that gamma delta T-cells can be endowed with a new generation of chimeric antigen receptors (CAR) that target tumour cells but avoid healthy cells. This strategy should reduce healthy cell background killing in immunotherapy to improve applicability and efficiency of this form of immunotherapies against cancer. This work was patented and then licensed to TC Pharma, Glasgow, UK. They have now received an investment of $15 million from BlueBirdBio, to fund clinical trials based on our work
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -